Compare AA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AA | IONS |
|---|---|---|
| Founded | 1888 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 13.5B |
| IPO Year | 2016 | 1996 |
| Metric | AA | IONS |
|---|---|---|
| Price | $61.91 | $81.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | $45.30 | ★ $85.14 |
| AVG Volume (30 Days) | ★ 6.6M | 1.8M |
| Earning Date | 04-23-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | ★ 1580.77 | 21.71 |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $12,831,000,000.00 | N/A |
| Revenue This Year | $9.98 | N/A |
| Revenue Next Year | $1.55 | $50.35 |
| P/E Ratio | ★ $17.78 | $115.15 |
| Revenue Growth | ★ 7.87 | N/A |
| 52 Week Low | $21.53 | $23.95 |
| 52 Week High | $66.95 | $86.74 |
| Indicator | AA | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 46.16 |
| Support Level | $55.17 | $79.78 |
| Resistance Level | $65.87 | $82.85 |
| Average True Range (ATR) | 3.24 | 2.60 |
| MACD | 0.14 | -0.40 |
| Stochastic Oscillator | 62.70 | 27.48 |
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is one of the world's largest bauxite miners and alumina refiners by production volume, but sits outside the top-10 aluminum producers, a list dominated by Chinese companies. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.